Global Brain Tumor Therapeutics Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4388564
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 4
The global brain tumor therapeutics market was estimated at USD XX million in 2015 and is expected to reach USD XX million by 2021, growing at a CAGR of X% during the forecast period 2016 to 2021.

Brain tumor, also known as intracranial neoplasm, is the abnormal growth of cells from within the brain; brain tumor can be malignant and benign. The malignant tumors can be classified into primary and secondary. While primary tumors start within the brain, secondary tumors, also called as brain metastasis tumors, are those that spread from other body parts. There are different types of brain tumors that include glioma, meningioma, pituitary adenoma, schwannomas and medulloblastoma. As per the National Cancer Institute estimates, 23,770 new cases of brain tumor were diagnosed in 2016, in the United States itself. The statistics estimate that more than 4,000 children and teens were diagnosed with brain tumor. The National Cancer Institute, USA, states that at least 33.8% such patients survive for five years.

Market Dynamics - Brain Tumor Therapeutics

The key factors driving this market are -

Increasing incidence and prevalence of brain cancer

Innovations in drug delivery (to brain cancer cells)

New product launches

The factors restraining the market are -

Limited availability of drugs that are specific to brain cancer

High cost of treatment

Increasing use of Generics in chemotherapy

Market Segmentation

The market has been segmented based on the radiation therapy, chemotherapy, and targeted therapy. Chemotherapy includes drugs such as Carboplatin, Carmustine, Cisplatin, Cyclophosphamide, Etoposide, Irinotecan, Lomustine, Methotrexate, Procarbazine, Temozolomide and Vincristine and targeted therapy includes Avastin.

Geographically, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.

The key players in this market are -

This Report Offers:

Market definition, along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 General Study Assumptions
1.4 Report Descritption
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Model
2.4 Research Assumptions
3. Executive Summary
4. Market Overview and Industry Trends
4.1 Current Market Scenario
4.2 Porter's Five Forces
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Consumers
4.2.3 Threat of New Entrants
4.2.4 Threat of Substitute Products and Services
4.2.5 Competitive Rivalry Within the Industry
5. Market Drivers, Restraints, Opportunities and Challenges
5.1 Market Drivers
5.1.1 Increasing Incidence and Prevalence of Brain Cancer
5.1.2 Huge Market for Treatment of Brain Cancer Associated Symptoms
5.1.3 Innovations in Drug Delivery to Brain Cancer Cells
5.2 Market Restraints
5.2.1 Very Few Brain Cancer Specific Drugs
5.2.2 Very High Cost of Treatment
5.2.3 Increasing Use of Generics in Chemotherapy
5.3 Market Opportunities
5.3.1 Cancer Tumors in Unreachable Parts of Brain
5.4 Market Challenges
5.4.1 Surgery Being the Most Effective Treatment Method
6. Market Segmentation
6.1 By Brain Cancer Type
6.1.1 Glioma
6.1.1.1 Astrocytoma
6.1.1.2 Oligodendroglioma
6.1.1.3 Ependymoma
6.1.1.4 Choroid Plexus Papilloma
6.1.2 Meningioma
6.1.3 Pituitary Adenoma
6.1.4 Schwannomas
6.1.5 Medulloblastoma
6.2 By Therapeutics
6.2.1 For Brain Cancer
6.2.1.1 Radiation Therapy
6.2.1.1.1 X-Ray Therapy
6.2.1.1.2 Gamma-Ray Therapy
6.2.1.2 Chemotherapy
6.2.1.2.1 Systemic Chemotherapy
6.2.1.2.1.1 Carboplatin
6.2.1.2.1.2 Carmustine (BCNU)
6.2.1.2.1.3 Cisplatin
6.2.1.2.1.4 Cyclophosphamide
6.2.1.2.1.5 Etoposide
6.2.1.2.1.6 Irinotecan
6.2.1.2.1.7 Lomustine (CCNU)
6.2.1.2.1.8 Methotrexate
6.2.1.2.1.9 Procarbazine
6.2.1.2.1.10 Temozolomide
6.2.1.2.1.11 Vincristine
6.2.1.2.2 Local chemotherapy
6.2.1.2.2.1 Carmustine Wafers
6.2.1.3 Targeted Therapy
6.2.1.3.1 Bevacizumab
7. Geographic Segmentation
7.1 North America
7.1.1 United States
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 UK
7.2.3 France
7.2.4 Italy
7.2.5 Spain & Portugal
7.2.6 Scandinavia
7.2.7 Benelux
7.2.8 Rest of Europe
7.3 Asia-Pacific
7.3.1 China
7.3.2 Japan
7.3.3 India
7.3.4 Australia & New Zealand
7.3.5 South Korea
7.3.6 Rest of Asia-Pacific
7.4 The Middle East and Africa
7.4.1 GCC
7.4.2 South Africa
7.4.3 Rest of the Middle East and Africa
7.5 Latin America
7.5.1 Brazil
7.5.2 Argentina
7.5.3 Rest of Latin America
8. Competitive Landscape
8.1 Drugs in Pipeline/New Product Launches
8.2 Mergers and Acqisitions
8.3 Agreement, Collaboration and Partnerships
9. Company Profiles
9.1 AstraZeneca
9.2 Bayer
9.3 Beckman Coulter
9.4 Bristol Myer Squibb
9.5 Eisai
9.6 Merck & Co
9.7 Novartis
9.8 Novocure
9.9 Pfizer
9.10 Roche
10. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll